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Bladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the 
sixth most prevalent cancer worldwide. Of all newly diagnosed patients with BC, 70–75% 
will present disease confined to the mucosa or submucosa, the non-muscle-invasive BC 
(NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). 
Due to high rate of recurrence, patients are submitted to an intensive follow-up program 
maintained throughout many years, or even throughout life, resulting in an expensive 
follow-up, with cystoscopy being the most cost-effective procedure for NMIBC screening. 
Currently, the gold standard procedure for detection and follow-up of NMIBC is based on 
the association of cystoscopy and urine cytology. As cystoscopy is a very invasive approach, 
over the years, many different noninvasive assays (both based in serum and urine samples) 
have been developed in order to search genetic and protein alterations related to the 
development, progression, and recurrence of BC. TERT promoter mutations and FGFR3 
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INTRODUCTION
Bladder cancer is the most frequent malignancy involving the 
urinary system and affects approximately four times more males 
than females (Miyazaki and Nishiyama, 2017). Worldwide, 
bladder cancer is the sixth most diagnosed cancer in men; when 
considering both genders, it ranks the 10th most diagnosed and 
the sixth position in prevalence (Ferlay et al., 2018; Ferlay et al., 
2019). Of all patients newly diagnosed with bladder cancer, 
around three quarters present disease confined to the mucosa or 
submucosa (Sanli et al., 2017), the so-called, non-muscle-invasive 
bladder cancer (NMIBC) subtype (Babjuk et al., 2018). The 
remaining are classified as muscle invasive bladder cancer 
(MIBC), reflecting their capacity to infiltrate the muscle layer of 
the bladder (Alfred Witjes et al., 2017; Sanli et al., 2017). The 
current treatment for NIMBC is transurethral resection (TUR); 
following TUR treatment, 70% of the NMIBC patients will recur 
after primary tumor removal and 10–20% will recur as MIBC, 
with the capacity to progress and develop metastatic disease 
(Kaufman et al., 2009; van der Heijden, 2009; Chamie et al., 
2013). This high rate of recurrence requires that patients are 
submitted to an intensive follow-up program. Major guidelines 
from the European Association of Urology (EAU) and American 
Urological Association (AUA) recommend cystoscopy and 
urinary cytology that, depending from the grade, can be as often 
as every 3 months in the first 2 years, semi-annually during the 
subsequent 3 years, and annually thereafter (Kassouf et al., 2016; 
Alfred Witjes et al., 2017; Babjuk et al., 2018). This intensive 
follow-up is maintained throughout many years following the 
initial diagnosis and indicates bladder cancer as a type of cancer 
with the most expensive follow-up (Kamat et al., 2011; Yeung et 
al., 2014). Cystoscopy is invasive and uncomfortable for patients 
due to the technical requirements of the procedure; still, it 
renders the more accurate diagnosis method for bladder cancer 
(Geavlete et al., 2012). Contrary to cystoscopy, noninvasive urine 
cytology is an economical approach, easier to perform, and when 
high-grade tumors are considered, the sensitivity is high (84%). 
The major limitation of urine cytology is its overall sensitivity to 
detect low-grade tumors (NMIBC), where the sensitivity 
decreases to 16%, precluding its use in the detection of those 
lesions (Yafi et al., 2015). The combination of all these facts leads 
to the opportunity for developing new, alternative, and minimally 
invasive methods to detect bladder cancer. As urine is in direct 
contact with the inner part of the bladder, cells from the 
epithelium, including scammed cells from bladder tumors, can 
exfoliate and be detected in urine and used to evaluate and 
monitor the presence of neoplasia in a noninvasive approach 
(Botezatu et al., 2000; Zwarthoff, 2008; Ralla et al., 2014; Critelli 
et al., 2016; Togneri et al., 2016). Over the years, many different 
noninvasive assays have been developed in order to search 
genetic and protein alterations known to be involved in the 
development, progression, and recurrence of bladder cancer, 
both in serum and urine samples, with the purpose to diagnose 
and monitor bladder cancer (Soloway et al., 1996; Fradet and 
Lockhard, 1997; Pode et al., 1999; Kruger et al., 2003; Tetu et al., 
2005; Moonen et al., 2007; Halling and Kipp, 2008; Serizawa et 
al., 2011; Goodison et al., 2012; Kinde et al., 2012; Kinde et al., 
2013; Allory et al., 2014; Bansal et al., 2014; Hurst et al., 2014; 
Ralla et al., 2014; Wang et al., 2014; Ellinger et al., 2015; Yafi et al., 
2015; Springer et al., 2018; Miyake et al., 2018). Some of these 
tests presented values of sensitivity and specificity higher than 
urinary cytology and achieved FDA approval for bladder cancer 
diagnosis. Despite high sensitivities and specificities, all these 
molecular assays present inconvenient rates of false-positive 
results (Hajdinjak, 2008; Dimashkieh et al., 2013; Gopalakrishna 
et al., 2017; Springer et al., 2018). False-positive rates could result 
from several factors, including the presence of benign conditions 
as hematuria, cystitis, lithiasis, urinary tract infections, and 
hotspot mutations are the most frequent somatic alterations in BC and constitute the most 
reliable biomarkers for BC. Based on these, we developed an ultra-sensitive, urine-based 
assay called Uromonitor®, capable of detecting trace amounts of TERT promoter (c.1-124C 
> T and c.1-146C > T) and FGFR3 (p.R248C and p.S249C) hotspot mutations, in tumor 
cells exfoliated to urine samples. Cells present in urine were concentrated by the filtration of 
urine through filters where tumor cells are trapped and stored until analysis, presenting long-
term stability. Detection of the alterations was achieved through a custom-made, robust, 
and highly sensitive multiplex competitive allele-specific discrimination PCR allowing clear 
interpretation of results. In this study, we validate a test for NMIBC recurrence detection, using 
for technical validation a total of 331 urine samples and 41 formalin-fixed paraffin-embedded 
tissues of the primary tumor and recurrence lesions from a large cluster of urology centers. In 
the clinical validation, we used 185 samples to assess sensitivity/specificity in the detection 
of NMIBC recurrence vs. cystoscopy/cytology and in a smaller cohort its potential as a 
primary diagnostic tool for NMIBC. Our results show this test to be highly sensitive (73.5%) 
and specific (93.2%) in detecting recurrence of BC in patients under surveillance of NMIBC.
Keywords: non-muscle invasive bladder cancer, TERT promoter mutation, FGFR3 mutation, urinary test, Uromonitor®
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inflammation or even because of repeated instrumentation, such 
as cystoscopy (Parker and Spiess, 2011; Dal Moro et al., 2013). A 
meta-analysis about the performance of urinary biomarkers 
concluded that most of the available urinary biomarkers do not 
detect the presence of bladder cancer in a proportion of patients 
and allow false-positive results in others, more frequently in low-
stage and low-grade tumors (Chou et al., 2015). So, more reliable 
biomarkers and assays are needed for earlier detection of bladder 
cancer recurrence, particularly in low-grade and low-stage 
NMIBC. Long non-coding RNAs (lncRNAs) have emerged as 
potential biomarkers since aberrant expression has been reported 
in bladder cancer, some upregulated (lncRNA urothelial cancer 
associated 1 and lncRNA metastasis-associated lung 
adenocarcinoma transcript 1) (Wang et al., 2008; Han et al., 
2013), and others downregulated such as maternally expressed 3 
(MEG3) (Ying et al., 2013). Some new potential therapeutic 
targets were also described, such as MIR503 host gene 
(MIR503HG) and lncRNA MALAT-1 (Ying et al., 2012; Qiu 
et  al., 2019). Recently, telomerase reverse transcriptase (TERT) 
promoter methylation aberration has been found in a large 
number of cancers, in a region described as TERT hypermethylated 
oncological region (THOR). THOR hypermethylation has been 
found as an alternative telomerase-activating mechanism in 
cancer that can act independently or in conjunction with TERT 
promoter mutations, further supporting the utility of THOR 
hypermethylation as a prognostic biomarker (Lee et al., 2018). 
Other studies highlight that both THOR hypermethylation and 
TERT promoter mutations are common and coexist in bladder 
cancer, and while TERT promoter mutation behaves as an early 
event in bladder carcinogenesis, THOR hypermethylation seems 
associated with disease progression, with the combined genetic 
and epigenetic alterations of TERT bringing additional prognostic 
value in NMIBC (Leão et al., 2019). TERT promoter mutations 
per se emerged as a novel biomarker detected in up to 80% of 
bladder cancer, independently of stage or grade (Rachakonda 
et al., 2013; Allory et al., 2014; Hurst et al., 2014; Hosen et al., 
2015). TERT promoter (TERTp) mutations are the most common 
event across stages and grades in malignant bladder tumors, 
strongly suggesting its participation in the two major genetic 
pathways of urothelial tumorigenesis (Allory et al., 2014; Hurst 
et  al., 2014). These features point TERTp mutations as a game 
changer in bladder cancer and pointed them to be considered as 
a useful urinary biomarker for disease monitoring and early 
detection of recurrence, even in low-grade NMIBC, where 
urinary cytology usually lacks sensitivity (Allory et al., 2014; 
Hurst et al., 2014; Vinagre et al., 2014; Descotes et al., 2017). 
TERTp mutations are not present in inflammatory or urinary 
infections, different from previously described urinary 
biomarkers (Raitanen et al., 2001; Chou et al., 2015; Descotes 
et al., 2017). TERTp mutations assumed a novel pivotal role, even 
surpassing the frequency of the oncogene-activating mutations 
in fibroblast growth factor receptor 3 (FGFR3) gene in NMIBC 
(Netto, 2011; Humphrey et al., 2016), one of the most relevant 
drivers of urothelial transformation. Cappellen et al. reported 
FGFR3 mutations in bladder cancer with a frequency of 35%, and 
subsequent studies established this frequency in approximately 
half of the primary bladder tumors (Cappellen et al., 1999; Sibley 
et al., 2001). Several studies report its presence in up to 80% 
regarding early-stage and low-grade tumors and as absent or a 
very rare event in high-grade and invasive tumors (Billerey et al., 
2001; van Rhijn et al., 2003; Hernandez et al., 2006; Tomlinson 
et  al., 2007; Pandith et al., 2013). FGFR3 assumes also an 
important role as a predictive biomarker due to the development 
of FGFR3-targeted therapies. KRAS mutations, although found 
in a lower percentage (11.5%) of bladder cancers, are assuming a 
relevant position since the detection of KRAS mutations in 
conjunction with the previous alterations could improve the 
sensitivity of a biomarker panel (Alexander et al., 2012).
The uniqueness of TERTp mutations, mainly its location in a 
promoter region with a GC base pair content >50% precluded that 
traditional methods using standardized conditions (conventional 
real-time assays or even next-generation sequencing techniques) 
could be used with an efficient output. With this goal in mind, we 
developed an ultra-sensitive assay based on real-time PCR (with 
a proprietary reaction chemistry and probes), a urine-based 
test capable of detecting trace amounts of the most common 
alterations in NMIBC, TERTp c.1-124C > T, c.1-146C > T, and 
FGFR3 p.R248C, p.S249C hotspot mutations, in urine samples.
MaTeRIal aND MeThODS
All procedures described in this study were in accordance with 
national and institutional ethical standards and the Declaration 
of Helsinki. Written informed consent was obtained from the 
patients participating in the study. Procedures were previously 
approved by Ethical Review Committee IPO-Coimbra (03/
TI/15). Inclusion and exclusion criteria for each analysis are 
detailed in Supplementary Table 1.
Sample Collection
Urine Samples
Urine samples from each participating urology center were 
collected and processed for delivery during routine urology 
appointments and previously to cystoscopy intervention, 
according to Uromonitor recommendations. Urine samples were 
filtered through a pretreated 0.80-µm nitrocellulose syringe filter 
(Whatman® Filter—Z612545, Merck, Germany) containing a 
homemade conservative storage buffer (10 mM glutathione, 1 M 
lithium chloride–6 M urea–30 mM Biuret, 2 M EDTA (E7889-
100ML) (information on this process is available in the video 
on the Supplementary—Video 1). Filters were then sent to the 
central lab at Ipatimup/I3S (Porto, Portugal). After arrival, filters 
were stored at 2–8°C for a maximum of 1 month until DNA 
extraction procedure.
Tissue Samples
Formalin-fixed paraffin-embedded (FFPE) tissues from primary 
tumor and/or from recurrent lesions from the cohort in study 
were obtained from the repository of tumors of the Instituto 
Português de Oncologia de Coimbra Francisco Gentil, E.P.E 
(IPOC-FG). Clinicopathological and follow-up data were 
retrieved from the files of the Department of Pathology of 
IPOC-FG.
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Cohort’s Characteristics—Urine and 
FFPe Cohorts
We studied a total of 372 samples (331 urine samples and 41 FFPE) 
collected from 18 urology centers (Supplementary Table  2). 
Technical validation of the assay was done in an independent 
setting where we studied a total of 334 samples from urine and 
FFPE (presented below). Clinicopathological and follow-up data 
were retrieved from the files of the centers involved in this study 
(Supplementary Figures 1 and 2).
The main aim of our study was to validate our new molecular 
panel in samples obtained through noninvasive procedures. For 
this, we performed technical validation by analyzing a total of 
331 urine samples. The clinical validation was performed by 
accessing the test’s ability to correctly detect patients who do have 
the condition, by calculating the ratio between the number of the 
test true positives and the total number of patients that harbor 
active disease (sensitivity). Also, specificity, the test’s ability 
to correctly reject healthy patients without a condition, was 
calculated with the ratio between the number of true negatives 
obtained by the test and the total number of patients that do not 
harbor disease at the time of the test. Positive predictive value 
(PPV) (ratio between test true positives and all the test positives) 
and negative predictive value (NPV) (ratio between test true 
negatives and all the test negatives) were also calculated, aiming 
at knowing after the test result, the probability that the patient 
has (or does not have) the disease. All these calculations were 
done using data from 185 patients.
Thus, urine samples from 185 patients (77% males and 33% 
females), with a median age of 71 years (range, 25–91) Table 1, 
were used and were subdivided into independent groups (that 
may overlap samples) (Table 2).
FFPE tissues of the primary tumor (n = 9) and/or of the 
recurrence lesions (n = 32) were also analyzed to test the 
performance of this assay in a different biological sample (FFPE) 
other than urine.
Cystoscopy, Cytology, and Tumor Resected 
Evaluation
Cystoscopy was considered positive when an unequivocal lesion 
deserving surgical treatment (despite the pathology result of the 
resected lesion) was observed by the urologist. Urine cytology and 
tissue pathology were performed by each pathology department 
from each center. In 41 cases, the diagnosis was confirmed in the 
histological examination of the lesion in the TUR.
DNa extraction
Urine Samples
Filters used for urine filtration were stabilized at room 
temperature for 30 min. Upon filtration, quality DNA for further 
processing is obtained on filters that can be stored at 4°C, up to 
3 months (Supplementary Figure 3). In an inverted position, 
filters were attached to a 2-ml microcentrifuge tube and a cell 
lysis solution was injected through each filter and collected in 
a microcentrifuge tube. Filtered lysates were incubated at 60°C 
for 30 min with 30 µl of proteinase K at 10 mg/ml, exposed 
to chaotropic lysis/binding buffer (Citogene Cell Lysis Buffer, 
Citomed, Portugal) to release nucleic acids and protect the 
genomic DNA from DNases. The microcentrifuge tube content 
was then processed according to the manufacturer’s protocol 
of the Norgen® Plasma/Serum Cell-Free Circulating DNA 
Purification Mini Kit (Norgen Biotek Corp, Canada).
TaBle 1 | Clinical validation cases information and clinicopathological data.
Characteristics Total cases (n = 185)
Age (years)
Median age (range) 71 (25–91)
Age cluster, n (%)
20–39 9 (4.9)
40–59 39 (21.3)
60–79 102 (55.7)
80+ 33 (18.0)
Gender, n (%)
Female 41 (23.2)
Male 136 (76.8)
Smoking status, n (%)
Yes/Former 45 (39.5)
No 69 (60.5)
Disease status, n (%)
Primary 122 (65.9)
Recurrence 63 (34.1)
Stage, n (%)
Cis/Tis 5 (9.8)
Ta 32 (62.7)
T1 12 (23.5)
T2 1 (2)
Hep.Met 1 (2)
Grade, n (%)
Low grade 25 (51)
High grade 24 (49)
Urine cytology, n (%)
Positive/atypical cytology 12 (14.3)
Negative cytology 72 (85.7)
Cystoscopy, n (%)
Positive 65 (35.2)
Negative 120 (64.8)
TaBle 2 | Cohorts used in this study.
Cohort name Cohort designation No. of samples
Follow-up cohort Urine samples from patients 
under follow-up for NMIBC
122
Initial diagnosis cohort Urine samples from patients 
screened for bladder cancer
63
Tumor samples cohort FFPE samples from primary 
tumors and recurrence from 
patients under follow-up for 
NMIBC
41
Uromonitor + KRAS 
follow-up cohort
Urine samples from 
patients under follow-up for 
NMIBC screened for both 
Uromonitor® and KRAS 
hotspot alterations
24
Uromonitor + KRAS 
initial diagnosis cohort
Urine samples from patients 
screened for bladder cancer 
for both Uromonitor® and 
KRAS hotspot alterations
25
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Tissue Samples
DNA from FFPE tissues was retrieved from 10-µm cuts after 
careful manual dissection. Slides were deparaffinized in xylene 
(2 × 10 min), followed by incubation in 100% alcohol (2 × 5 
min). Tumor tissue was removed from the slides into a 1.5-ml 
microcentrifuge tube. DNA extraction was performed using the 
Ultraprep Tissue DNA Kit (AHN Biotechnologie, Germany) 
according to the manufacturer’s instructions. The DNA 
extracted was quantified by spectrophotometry using Nanodrop 
ND-1000, and quality was assessed by analysis of 260/280 and 
260/230-nm ratios.
Urine Testing Workflow
The Uromonitor® is a custom-made full working procedure 
developed and optimized for the detection in a real-time PCR 
platform of oncogene hotspot mutations in bladder cancer tumor 
cells, exfoliated to urine, particularly TERTp c.1-124C > T, TERTp 
c.1-146C > T, FGFR3 p.R248C, and FGFR3 p.S249C alterations 
(Figure 1). All the tests done in this study were performed in the 
central lab at Ipatimup/I3S by the same lab professional, ensuring 
minor variability in data creation and analysis.
Mutation detection is achieved by real-time PCR amplification 
curve analysis. Positive and negative mutation control samples are 
included in each run to ensure the assay’s validity. For TERTp c.1-
124C > T and c.1-146C > T alteration screening, we developed an 
improved real-time allelic discrimination assay (further referred 
to in the text as TERT-124 and TERT-146 assays), with the use of 
Locked Nucleic Acid (LNA probes) (Figures 2A, B). LNA probes 
allowed modulating the melting temperature on specific bases 
of the probe, enhancing the possibility to achieve preferential 
melting temperatures in short probe sequences. LNA probes 
greatly improve allelic discrimination, allowing higher stability 
on the binding to a specific target even with a shorter sequence. 
When in the presence of a base pair mismatch, such specificity is 
lost due to a large melting temperature difference. This leads to 
the impossibility for the LNA probe to bind to a sequence that 
contains only one base pair mismatch. This high specificity to 
the target sequence renders this type of probe perfect for allelic 
discrimination experiments (Supplementary Figure 4).
For FGFR3 mutations selected for screening (p.R248C and 
p.S249C), we designed for each mutation a competitive allele-
specific real-time detection PCR (further referred to in the text 
as FGFR3 248 and FGFR3 249 assays), based on the design of a 
mutation allele primer, a wild-type allele blocker, a locus reverse 
primer, and a fluorescent probe for real-time detection of the 
generated amplicon (Figures 2C, D). The use of a molecular 
blocker suppressed the amplification of the wild-type allele in 
order to not interfere with the amplification of the mutant allele. 
By this technique, we improved current detection limit for the 
selected alterations compared to Sanger sequencing, enhancing 
the ability to detect a minimal quantity of altered cells in a large 
pool of cells without alterations.
In this work, we also present preliminary results on the high-
sensitivity screening of KRAS codon 12 and codon 61 alterations 
achieved through the use of a custom-made mutation detection 
FIgURe 1 | Urine testing workflow. In patients under surveillance for non-muscle-invasive bladder cancer (NMIBC), a minimum of 10 ml of urine is collected before 
cystoscopy. This 10 ml of urine is then filtered through a 0.8-µm filter and stored at 4°C. DNA extraction and Uromonitor® test are then performed. If a positive result 
is obtained, confirmatory cystoscopy and transurethral resection of eventual recurrences are recommended. If a negative result is obtained, it is recommended that 
the test should be repeated on next follow-up appointment.
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procedure developed similarly to FGFR3 hotspot mutation 
detection procedure, rendering this method suitable for detection 
of mutations in bladder cancer tumor cells exfoliated to urine.
TERT, FGFR3, and preliminary KRAS testing was performed 
in approximately 25 ng of DNA extracted from cells in each 
filtered urine, or from 25 ng of DNA extracted from FFPE 
tissues, either primary tumor and/or recurrent lesions. The 
extracted DNA was amplified and detected on a qPCR real-time 
machine using the proprietary chemistry for amplification and 
detection as provided in the Uromonitor® test kit for the targeted 
nucleotide changes in TERTp and FGFR3 genes.
Uromonitor® Technical Validation
Uromonitor® precision was analyzed by a reproducibility test. 
To achieve this, 10 samples were amplified and analyzed using 
Uromonitor® test (eight samples harboring mutations and two 
wild-type samples for the alterations of interest). These samples 
were amplified five times for each alteration, 1 week apart of each 
amplification, for 5 weeks. Uromonitor® accuracy was analyzed 
by two independent tests. First, it was necessary to ensure that a 
test containing a sample without DNA or with DNA that does 
not harbor any of the alterations of interest did not generate 
an analytical signal that may indicate a low concentration of 
mutation (analytical false positive). It was also necessary to 
assess the accuracy of the results produced by Uromonitor® 
test comparing it to the standard method in the detection of the 
alterations in study (Sanger sequencing). All the samples were 
validated by Sanger sequencing for the alterations in study.
Uromonitor® Precision and Accuracy in Urine 
Samples
To test accuracy in urine samples, 36 samples negative for all 
the mutations in study (status obtained by Sanger sequencing) 
and 36 “blank” samples (without DNA) were amplified for each 
alteration (false-positive testing). 
Also, 252 blind tests from urine samples were analyzed (73 
tests for TERTp −124 assay, 72 tests for TERTp −146 assay, 55 
tests for FGFR3 248 assay, and 52 tests for FGFR3 249 assay).
Uromonitor® Precision and Accuracy in FFPE 
Tissue Samples
Uromonitor® test could also be used to screen FFPE samples in 
patients with a history of NMIBC. To test accuracy in FFPE tissue 
samples, nine samples negative for all the mutations in study 
FIgURe 2 | Technical principles of the test. (a) Real-time qualitative method optimized for TERTp c.1-124C > T detection. Two competitive fluorescent probes 
targeting normal (WT- c.1-124C) and mutated (Mut- c.1-124C > T) alleles incorporating Locked Nucleic Acid bases are used to detect the mutations. (B) Real-time 
qualitative method optimized for TERTp c.1-146C > T detection. Two competitive fluorescent probes targeting normal (WT- c.1-146C) and mutated (Mut c.1-146C > 
T) alleles incorporating Locked Nucleic Acid bases are used to detect the mutations. (C) Real-time qualitative method optimized for FGFR3 c.742C > G detection. A 
mutation allele-specific primer, a phosphorylated wild-type allele blocker that completely suppresses the amplification of the wild-type allele, a locus reverse primer, 
and a fluorescent probe for real-time detection of the generated amplicon are used. (D) Real-time qualitative method optimized for FGFR3 c.746C > T detection. A 
mutation allele-specific primer, a phosphorylated wild-type allele blocker that completely suppresses the amplification of the wild-type allele, a locus reverse primer, 
and a fluorescent probe for real-time detection of the generated amplicon are used.
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(status obtained by Sanger sequencing) and 36 “blank” samples 
(without DNA) were amplified for each alteration (false-positive 
testing). Also, 483 tests from FFPE tissue samples were analyzed 
(201 tests for TERTp −124 assay, 200 tests for TERTp −146 assay, 
41 tests for FGFR3 248 assay, and 41 tests for FGFR3 249 assay).
TERTp Detection Limit Assessment
Uromonitor® includes TERTp alteration detection by real-time 
PCR by LNA allelic discrimination probes. High GC content 
and thorough optimization of the amplified TERTp alterations 
characterize this innovative test. Since TERTp mutation detection 
by current methods has low sensitivity, there was the need to 
assess the detection limit for TERTp alterations included by the 
technology in the Uromonitor®. To achieve this, we performed 
twofold serial dilutions of genomic DNA containing the studied 
alteration (100% of mutated DNA) in genomic DNA wild type 
for the studied alterations. Serial dilutions were amplified for 
the corresponding detection assay. This procedure was repeated 
for both TERTp alterations that comprise the Uromonitor® test 
(Figure 3).
Statistical Analysis
Statistical analysis was performed using 21.0 SPSS Statistical 
Package (SPSS, Inc., 220, 2003). Descriptive statistic was 
done and the results are expressed as percentages and mean ± 
standard deviation.
FIgURe 3 | (a) Serial dilution detection of TERTp c.1-124C > T. TERTp c.1-124C > T mutated DNA with 50% (wild-type) WT/mutation ratio was diluted in a twofold 
dilution (eight dilutions) in WT DNA. Detection limit was fixed at the presence of 6.25% of TERTp c.1-124C > T alteration in the total DNA in a reaction with 25 ng of 
total DNA. Below this limit, mutation detection is not guaranteed. (B) Serial dilution detection of TERTp c.-146C > T. TERTp c.1-146C > T mutated DNA with 50% 
WT/mutation ratio was diluted in a twofold dilution (eight dilutions) in WT DNA. Detection limit was fixed at the presence of 6.25% of TERTp c.1-146C > T alteration 
in the total DNA in a reaction with 25 ng of total DNA. Below this limit, mutation detection is not guaranteed.
Frontiers in Genetics | www.frontiersin.org December 2019 | Volume 10 | Article 1237
Noninvasive Surveillance of NMIBCBatista et al.
8
ReSUlTS
genetic alterations Technical Validation
Uromonitor® precision was analyzed, achieving a 100% 
concordance in a reproducibility test. In urine samples accuracy 
tests (comparisons to Sanger sequencing), TERTp −124 assay 
achieved 100%, TERTp −146 assay 98.6%, FGFR3 248 assay 
87.3%, and FGFR3 249 assay 94.2%. Overall, Uromonitor® 
test presented a combined accuracy of 95.0%. Uromonitor® 
test accuracy in FFPE tissue samples (comparison to Sanger 
sequencing) achieved 98.5% for TERTp −124 assay, 99.5% for 
TERTp −146 assay, 90.2% for FGFR3 248 assay, and 97.6% for 
FGFR3 249. For all assays, Uromonitor® achieved a combined 
96.5% accuracy (Supplementary Table 3). The test presented 
no false positives in samples without DNA (blank samples). A 
combined accuracy lower than 100% is justified by the detection 
of positivity by real-time PCR in samples for which Sanger 
sequencing fails to detect alteration due to lack of sensitivity.
In all the assays, the analytical detection limit was 6.25% 
of mutant sequences in a background of wild-type DNA. The 
presence of altered DNA in less than 6.25% of the total DNA in 
the sample may not be detected.
Molecular Characterization of Urine Samples
From the initial cohort of 331 urine samples, 304 were fully 
characterized for the alterations targeted by Uromonitor® 
test and 27 failed one or more alterations. From these, TERTp 
mutations were detected in 50.6% of cases (39.0% presented the 
TERTp c.1−124C > T and 11.7% with the TERTp c.1−146C > T) 
and FGFR3 mutations were detected in 49.4% of cases (31.2% at 
codon 248 and 18.2% at codon 249 of FGFR3 protein). Further 
correlations with clinical data were performed for 185 samples 
where complete clinical data was available.
Clinical Validation
Recurrence Follow-Up Cohort
In the follow-up cohort (n= 122), 28% (n = 34) of the patients 
recurred (confirmed by histology) of the TUR, whereas the 
remaining 72% (n= 88) were negative for recurrence.
Uromonitor® Performance Comparison With Cytology and 
Cystoscopy Methods
We analyzed and compared follow-up recurrence detection 
of Uromonitor® in NMIBC in comparison to routinely used 
screening methods such as cystoscopy and/or cytology.
Uromonitor® sensitivity was 73.5% in the detection of TUR 
confirmed recurrence, with a specificity of 73.2% (Figure 4, 
Table 3 and Supplementary Table 4). The values were comparable 
and similar to gold-standard cystoscopy performance that in 
the follow-up series presented values of 79.4% and 73.2% for 
sensitivity and specificity, respectively (Figure 4, Table 3 and 
Supplementary Table 4).
Uromonitor® sensitivity performance was much higher than 
cytology (42.9% cytology sensitivity vs. 73.5% Uromonitor® 
sensitivity (Figure 4, Table 3 and Supplementary Table 4).
When cytology was combined with cystoscopy, they jointly 
achieved an increased sensitivity of 86.7% and a slightly 
decreased specificity of 87.9% due to the increased rate of 
cytology false positives (Figure 4, Table 3 and Supplementary 
Table 4). Although the combination with cytology presents an 
upgrade to cystoscopy per se, a greater benefit is obtained when 
combining Uromonitor® with cystoscopy, granting together a 
100% sensitivity and 88.6% specificity, clearly demonstrating 
an improvement in sensitivity and specificity relative to the 
“cystoscopy + cytology” screening method (Figure 4, Table 3 
and Supplementary Table 4).
To further improve Uromonitor® test performance, we 
analyzed a subset of samples (Uromonitor® + KRAS follow-up 
cohort) for another oncogene activated in bladder cancer, 
KRAS hotspot alterations, and compared follow-up recurrence 
detection to routinely used surveillance methods.
TERT/FGFR3/KRAS increased sensitivity to 100% in the 
detection of TUR confirmed recurrence with a specificity of 
83.3% (Figure 4, Table 3 and Supplementary Table 4). The values 
were higher when compared to cystoscopy performance that in 
the follow-up series achieved 79.4% and 73.2% for sensitivity and 
specificity, respectively (Figure 4, Table 3 and Supplementary 
Table 4). TERT/FGFR3/KRAS sensitivity performed higher than 
cytology (42.9% sensitivity and 93.9% specificity) (Figure 4, 
Table 3 and Supplementary Table 4).
Compared with cytology combined with cystoscopy, although 
this combination presents an interesting upgrade to cystoscopy 
per se, it does not achieve TERT/FGFR3/KRAS molecular 
testing performance per seor molecular testing in combination 
with cystoscopy screening method (Figure 4, Table 3 and 
Supplementary Table 4).
Genetic Alterations Distribution in Recurrences and 
Initial Diagnostic Positive Cases
Regarding the specific mutations detected in positive urine 
samples from the follow-up cohort, TERTp mutations were 
detected in 52.0% of cases (44.0% presented the −124C  > T 
and 8.0% with the −146C > T) and FGFR3mutations were 
detected in 40.0% of cases (28.0% at codon 248 and 12.0% at 
codon 249 of FGFR3 protein). Of the cases, 8.0% presented two 
concomitant alterations (two cases with TERTp c.1−124C > T 
and with alterations in codons 248 or 249 of FGFR3) (Figure 5).
Regarding the specific mutations detected in urine samples 
from the cohort of patients undergoing initial diagnosis, they 
were positive for Uromonitor assay as follows: TERTp mutations 
were detected in 35.7% of cases (21.4% presented the −124C > 
T and 14.3% the −146C > T mutation) and FGFR3 mutations 
were detected in 28.6% of cases (14.3% at codon 248 and 14.3% 
at codon 249 of FGFR3 protein). Of the cases, 35.7% presented 
TERTp and FGFR3 concomitant alterations (one case with c.1-
124C > T and p.R248C, one case with c.1-124C > T and p.S249C, 
one case with c.1-146C > T and p.S249C, and two cases with 
p.R248C and p.S249C alterations (Figure 5). Nine cases in the 
follow-up cohort and 14 cases in the initial diagnosis cohort did 
not present any of the TERTp or FGFR3 screened alterations 
(Figure 5).
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Uromonitor® Performance Correlation With Stage/Grade
Tumor stage information in cases positive for recurrence 
was available for 26 patients. The majority of recurrence-
positive cases were for stage Ta (50.0%), with T1 and Tis 
representing 27.0% and 19.2%, respectively (Figure 6 and 
Supplementary Table 5). Regarding the grade, the majority 
of recurrence-positive tumors were high grade (66.7%), with 
33.3% being the remaining low-grade cases (Figure 7 and 
Supplementary Table 6). In Cis/Tis recurrence-positive patients, 
Uromonitor® achieved a 100% detection rate, while in patients 
that recurred with a Ta tumor the detection rate was 53.8%. For 
T1 stage positive patients, the detection rate was 71.4% (Figure 6 
FIgURe 4 | Performance of different screening methods in non-muscle-invasive bladder cancer (NMIBC) follow-up recurrence detection and in NMIBC diagnosis.
TaBle 3 | Performance of different screening methods in non-muscle-invasive bladder cancer (NMIBC) follow-up recurrence detection and in NMIBC initial diagnosis.
UROMONITOR CYSTOSCOPY Cytology Cystoscopy + 
cytology
UROMONITOR + 
cystoscopy
UROMONITOR 
+ KRAS
Follow-up cohort
Sensitivity 50.0 79.4 42.9 86.7 100.0 100
Specificity 100.0 93.2 93.9 87.9 86.4 83.3
accuracy 77.8 89.3 78.7 87.5 90.2 87.5
PPV 100.0 81.8 75.0 76.5 73.9 66.7
NPV 71.4 92.1 79.5 93.5 100.0 100
Initial diagnosis cohort
Sensitivity 50.0 100.0 0.0 100.0 100.0 93.3
Specificity 100.0 88.6 86.7 86.7 88.6 80.0
accuracy 77.8 93.7 70.3 89.2 93.7 88.0
PPV 100.0 87.5 0.0 63.6 87.5 87.5
NPV 71.4 100.0 78.8 100.0 100.0 88.9
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and Supplementary Table 7). In low-grade recurrence-positive 
patients, Uromonitor® achieved a 62.5% detection rate, while in 
patients that recurred with a high grade, Uromonitor® tumor 
detection rate was 75%. (Figure 7 and Supplementary Table 
8). One case (3.8%) presented a hepatic metastasis, positively 
detected in the urine sample by Uromonitor Uromonitor (Figure 
6 and Supplementary Table 5).
Initial Diagnosis Cohort Analysis
Uromonitor® Performance Comparison With 
Cystoscopy Method
We analyzed the diagnostic performance of the test in the initial 
diagnosis of bladder cancer in comparison to the usual screening 
methods such as cystoscopy and/or cytology.
Sensitivitywas 50.0% in an initial diagnosis setting, but with 
a specificity of 100%. These values are low in comparison with 
cystoscopy’s virtual sensitivity of 100%, although with a lower 
specificity of 88.6%, but are much better than cytology which did 
not have sensitivity (0%) and achieved 86.7% specificity.
We analyzed the performance of Uromonitor® + KRAS in the 
initial diagnosis of bladder cancer in comparison to cystoscopy 
and/or cytology. Uromonitor® + KRAS sensitivity was 93.3% in 
an initial diagnosis setting with a specificity of 80% (Figure 4, 
Table 3, and Supplementary Table 4).
DISCUSSION
TERT promoter mutations were firstly described in sporadic 
and familial melanoma (Horn et al., 2013; Huang et al., 2013), 
and since then they were reported in several cancers, such as 
central nervous system (43–51%), hepatocellular carcinoma 
(59%), thyroid (follicular cell-derived tumors) (10%), and 
notably in bladder cancer (59–80%) (Killela et al., 2013; Liu 
et al., 2013a; Liu et al., 2013b; Nault et al., 2013; Vinagre 
et al., 2013; Wu et al., 2014). For bladder cancer, the TERTp 
mutations are independent of stage or grade (Rachakonda 
et  al., 2013; Allory et al., 2014; Hurst et al., 2014; Hosen 
et al., 2015) and were reported in both non-muscle and 
muscle-invasive bladder cancer. As the current diagnosis 
and follow-up of patients with bladder cancer is highly 
invasive and expensive, new molecular markers are needed 
able to act in noninvasive approaches in order to select an 
optimal treatment and follow-up for each patient (Kurth 
et al., 1995; Pandith et al., 2013; van Kessel et al., 2013). 
For this purpose, we developed a novel urine-based real-
time assay (Uromonitor®), and in this study, we present the 
technical and clinical performance of the detection of critical 
FIgURe 5 | Mutation distribution across follow-up cohort (a) and initial-
diagnosis cohort (B).
FIgURe 6 | Cohort’s tumor stage distribution and Uromonitor performance in recurrence detection across tumor stages.
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alterations in TERT pregion and FGFR3in DNA obtained 
from scammed cells of bladder present in urine. The main 
goal of the test is to be able to predict recurrence in NMIBC 
per seor in combination with cystoscopy. In this study, we 
analyzed and compared its performance in the follow-up of 
recurrence and in an initial diagnosis setting in NMIBC and 
in comparison with routinely used screening methods such as 
cystoscopy and/or cytology. The first detected limitation of 
this study is the recurrence rate of only 28%. A value ranging 
60–70% would be expected, as reported in the literature for 
NMINBC following TUR treatment (Antoine and van der 
Heijden, 2009; Kaufman et  al., 2009; Chamie et al., 2013). 
The reason for this difference may reflect the restricted 2-year 
patients’ follow-up considered, or patient-related factors (age, 
gender, multiplicity, smoking status, and adjuvant treatment) 
associated with recurrence frequency that are not considered 
at the moment (Kobayashi et al., 2014).
The sensitivity and specificity of Uromonitor® assay in the 
detection of TUR confirmed recurrence in the follow-up series 
are comparable to cystoscopy performance and in accordance 
with the literature that describes that about 20% of primary 
tumors lack TERTp and FGFR3 alterations, rendering an 
empirical detection rate around 80%. The unsolved 20% of cases 
can be attributed to tumors and recurrences that may undergo 
different tumorigenic pathways other than the acquisition of 
TERTp and FGFR3 alterations that could preclude Uromonitor® 
testing capacity, like RASmutations (see below).
Among the recurrence-negative cases, the test was 
concordantly negative in 87.7% of cases. The mutational state 
of TERTp and FGFR3 genes in bladder cancer is considered a 
promising predictor of recurrence of NMIBC, demonstrated 
by the association between FGFR3mutation in primary 
tumor and later in recurrence events (Hernandez et al., 2006; 
Burger et al., 2008; Kompier et al., 2009; Miyake et al., 2010; 
Zuiverloon et al., 2010; van Rhijn et al., 2012). A specificity 
of 93.2% reflects the detection of three cases positive for 
FGFR3 mutations and three cases with TERTp mutations 
without evidence of recurrence by cystoscopy. These cases 
remained negative for recurrence during the 2-year follow-up, 
suggesting that they were false positives. TERTp mutations 
were extensively studied and are described in the literature 
as absent in normal tissue. Since a clear positive signal was 
obtained in the aforementioned cases, we cannot rule out the 
hypothesis that Uromonitor® high sensitivity may be detecting 
microscopic lesions and that may predict the appearance of a 
macroscopic lesion in a longer-term period beyond the 2-year 
follow-up.
More than half of the cases presented at least one 
mutational event, and it is reported that TERTp and FGFR3 
mutations tend to occur more frequently together than per 
chance; the combination of both constitutes a more reliable 
biomarker for NMIBC recurrence monitoring (Hosen et al., 
2015; Critelli et al., 2016).
Uromonitor® sensitivity performance was higher than 
cytology, and if used as an adjunct to cystoscopy it allowed 
achieving a 100% sensitivity and 88.6% specificity, an important 
upgrade in sensitivity and specificity in comparison to the 
cystoscopy and cytology combination. This data demonstrates 
that this test, used together with cystoscopy at a routine level, 
will lead to a cost-effectiveness increment. It can also be used per 
se without any decrease in performance relative to the current 
routinely used methods, such as cystoscopy or if cystoscopy is 
not routinely available.
Uromonitor® showed overall good performance in recurrence 
detection across all stages. In Cis/Tis tumors, which represent 
20% of follow-up positive cases, a peak performance was 
obtained with a 100% detection rate. For the majority of these 
Cis/Tis cases TERTp alterations were present (four out of five 
cases, 80.0%). Several authors reported that TERTp alterations 
are not associated with stage and FGFR3 hotspot alterations 
are rare in Cis/Tis tumors; this is concordant with our findings 
where only one patient presented a FGFR3 mutation.
This series was enriched with high-grade tumors, which is 
in contrast to the majority of the reported series of NMIBC. 
This might have created a bias in the results and impacted the 
assay performance. Development of this test is actively based 
in TERTp/FGFR3 alterations detection that together are more 
frequent in low-grade tumors; additionally, FGFR3 mutations are 
rare in high-grade tumors.
We also prospectively analyzed and compared initial diagnosis 
performance in comparison to routinely used screening 
methods. In an initial diagnosis setting, sensitivity was lower in 
FIgURe 7 | Cohort’s tumor grade and uromonitor performance in recurrence detection across tumor grades.
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the detection of disease compared to standard cystoscopy that 
is considered to virtually hold a 100% sensitivity (a value due to 
the absence of confirmation of tumor existence on cystoscopy 
negative cases) and 88.6% specificity. Among the negative 
cases, the Uromonitor® test was concordant in 100% of cases 
being highly specific. In comparison with another routine assay, 
Uromonitor® largely surpasses cytology’s sensitivity that could 
not detect any new bladder cancer-positive case (0% sensitivity).
Nevertheless, taking into consideration that Uromonitor® 
main performance was initially aimed for low-grade tumors, 
these series gave us the opportunity to improve Uromonitor® 
performance in a high-grade tumor-enriched setting. To this 
purpose, we included new biomarkers in the test in order to 
improve Uromonitor® detection rate and testing capabilities 
overall; we want to achieve and maintain the high sensitivity 
and specificity that our test offers. This led to the KRAS hotspot 
alterations inclusion, and this preliminary data demonstrated 
that, both for follow-up or initial diagnosis cases, Uromonitor® + 
KRAS improves significantly, reachin a 100% sensitivity in 
follow-up detection and 93.3% in initial-diagnosis detection and 
with an overall performance of 95.2% regardless of grade. With 
the inclusion of KRAS hotspot mutation screening together with 
Uromonitor®, this preliminary data presents this noninvasive 
approach as a true alternative to cystoscopy for NMIBC follow-up 
or even as a population screening and/or initial diagnosis for 
bladder cancer. It is also noteworthy to mention that the inclusion 
of FGFR3 in Uromonitor® test raises its usefulness as a biomarker 
test for targeted therapy.
During the course of this study, an interesting case 
demonstrated the capacities of these novel tests in providing 
new information regarding disease progression. In a patient 
apparently free of local disease, a TERTp mutation was detected 
in the urine. Although the patient did not present bladder cancer 
at the time, it had a hepatic metastasis. Further analysis confirmed 
that the hepatic metastasis presented a TERTp mutation. It will 
be worthwhile to investigate the usefulness of this test technology 
in the screening of other tumors and metastasis, namely, those 
harboring TERTp mutations, in urine samples.
In terms of the Uromonitor® performance in comparison with 
other available options, it presented improved features. Reviewed 
by Sapre et al. (2014), the sensitivity of other available options 
ranges from 50.0% to 96.6%, and the tests are based on different 
methodology approaches, some more technically challenging 
and maintaining invasive requirements for the procedure. 
Avoidance of invasive procedures for the patients was a concern 
in the development of this test since morbidity of cystoscopy is 
often underestimated and can impact on patient adherence, with 
surveillance rates as low as 40% (Schrag et al., 2003). The fact 
that the test is conducted in urine renders it safer for patient use 
and with better acceptance in comparison with conventional 
cystoscopy. Another important aspect in the development of 
Uromonitor® was the implementation ability across different 
centers or laboratories. For this, we concentrated on three pillars: 
ease of use, cost, and response time. Being a real-time PCR-based 
method, a technique that is already well implemented in most 
laboratories, not requiring a specialized technician to execute 
the test or dedicated apparatus, with affordable equipment and 
reduced costs, and, most determinately, with the capacity to 
output a result in 6 h. If we compare this approach with other 
established next-generation sequencing (NGS)-based methods, 
it is promptly detected that such a fast response is not possible 
as it is required to have a sample and library preparation, failing 
the short-time frame response, the costs would increase with run 
and equipment requirements and NGS equipment is not widely 
available. Also, if we compare this to current detection methods 
for TERTp and/or FGFR3 based on Sanger sequencing, the high 
increase in sensitivity is a key factor, especially since we are trying 
to detect trace amount of tumor cells in urine samples.
Overall, this study demonstrates that Uromonitor® represents 
a highly sensitive and specific urine test in detecting recurrence 
of NMIBC. Taking into account the obtained results, we can view 
Uromonitor®, with and without KRAS mutation screening, on 
different levels depending on the specific needs of the patient/
healthcare professional. Uromonitor® TERTp/FGFR3 screening 
could be easily used in direct substitution of cytology since 
it presents an undoubtfully higher overall sensitivity while 
maintaining analysis response time and costs at an equivalent 
level. On the other hand, Uromonitor® TERT/FGFR3/KRAS 
screening, based on our preliminary results, could directly 
substitute cystoscopy in a specific context, such as the impossibility 
of performing an cystoscopy, patients refusing to perform 
cystoscopy, or even alternating with cystoscopy in the follow-up 
program in patients with low-risk, low-grade lesions, alleviating 
the number of cystoscopy procedures that patients are required 
to undergo. The rate of Uromonitor® false positives was similar 
to the rate of cystoscopy false positives. Our results prompt us to 
validate these findings in an enlarged robust independent series, 
in an ongoing study with a design that includes a group of benign 
conditions (renal lithiasis, urinary infections, hyperplasia of the 
prostate, and others). We intend to further test it and externally 
validate it to assess its cost-effectiveness and to determine its 
value in patients’ follow-up.
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